Avion Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
US YC W20 medical drone delivery of pharma/blood/diagnostics to remote clinics; $4.73M seed 2024-2025 with eVTOL drones and autonomous routing competing with Zipline for rural healthcare supply chain access.
About
Avion Health is a United States-based drone-based medical supply delivery platform — backed by Y Combinator (W20) with $4.73 million in seed funding in 2024-2025 — providing healthcare facilities and communities with autonomous eVTOL (electric vertical take-off and landing) drone delivery of vital medical supplies including pharmaceuticals, blood products, and diagnostic samples, bridging the accessibility gap between remote clinics and urban healthcare infrastructure. Operating pilot programs across the United States and internationally, Avion's drones feature GPS tracking, autonomous route correction, and real-time diagnostics — delivering to hard-to-reach areas with significant time savings compared to ground transportation and enabling same-hour medical supply access in geographies where traditional logistics are too slow for clinical urgency. Founded in 2019.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.